Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3)

Subrata Ghosh; Lianne S. Gensler; Zijiang Yang; Chris Gasink; Soumya D. Chakravarty; Kamyar Farahi; Paraneedharan Ramachandran; Elyssa Ott; Bruce E. Strober

doi:10.1007/s40264-019-00816-3

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3)

Subrata Ghosh
, Lianne S. Gensler
, Zijiang Yang
, Chris Gasink
, Soumya D. Chakravarty
, Kamyar Farahi
, Paraneedharan Ramachandran
, Elyssa Ott
, Bruce E. Strober

Research output: Contribution to journal › Comment/Debate

Abstract

In the original publication of this article, the following correction should be noted in Table 5. The 95% CI for serious infections in the Ustekinumab -MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.

Original language	English
Pages (from-to)	809
Number of pages	1
Journal	Drug Safety
Volume	42
Issue number	6
DOIs	https://doi.org/10.1007/s40264-019-00816-3
Publication status	Published - 4 Jun 2019
Externally published	Yes

Access to Document

10.1007/s40264-019-00816-3

Fingerprint

Dive into the research topics of 'Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3)'. Together they form a unique fingerprint.

Cite this

Ghosh, S., Gensler, L. S., Yang, Z., Gasink, C., Chakravarty, S. D., Farahi, K., Ramachandran, P., Ott, E., & Strober, B. E. (2019). Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3). Drug Safety, 42(6), 809. https://doi.org/10.1007/s40264-019-00816-3

@article{6ad8cd4f5c084014880600488465e1b0,

title = "Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn{\textquoteright}s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3)",

abstract = "In the original publication of this article, the following correction should be noted in Table 5. The 95\% CI for serious infections in the Ustekinumab -MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.",

author = "Subrata Ghosh and Gensler, \{Lianne S.\} and Zijiang Yang and Chris Gasink and Chakravarty, \{Soumya D.\} and Kamyar Farahi and Paraneedharan Ramachandran and Elyssa Ott and Strober, \{Bruce E.\}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = jun,

day = "4",

doi = "10.1007/s40264-019-00816-3",

language = "English",

volume = "42",

pages = "809",

journal = "Drug Safety",

issn = "0114-5916",

publisher = "Adis",

number = "6",

}

Ghosh, S, Gensler, LS, Yang, Z, Gasink, C, Chakravarty, SD, Farahi, K, Ramachandran, P, Ott, E & Strober, BE 2019, 'Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3)', Drug Safety, vol. 42, no. 6, pp. 809. https://doi.org/10.1007/s40264-019-00816-3

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3). / Ghosh, Subrata; Gensler, Lianne S.; Yang, Zijiang et al.
In: Drug Safety, Vol. 42, No. 6, 04.06.2019, p. 809.

Research output: Contribution to journal › Comment/Debate

TY - JOUR

T1 - Correction to

T2 - Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3)

AU - Ghosh, Subrata

AU - Gensler, Lianne S.

AU - Yang, Zijiang

AU - Gasink, Chris

AU - Chakravarty, Soumya D.

AU - Farahi, Kamyar

AU - Ramachandran, Paraneedharan

AU - Ott, Elyssa

AU - Strober, Bruce E.

PY - 2019/6/4

Y1 - 2019/6/4

N2 - In the original publication of this article, the following correction should be noted in Table 5. The 95% CI for serious infections in the Ustekinumab -MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.

AB - In the original publication of this article, the following correction should be noted in Table 5. The 95% CI for serious infections in the Ustekinumab -MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.

UR - https://www.scopus.com/pages/publications/85064702543

U2 - 10.1007/s40264-019-00816-3

DO - 10.1007/s40264-019-00816-3

M3 - Comment/Debate

C2 - 31012051

AN - SCOPUS:85064702543

SN - 0114-5916

VL - 42

SP - 809

JO - Drug Safety

JF - Drug Safety

IS - 6

ER -

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (Drug Safety, (2019), 42, 6, (751-768), 10.1007/s40264-019-00797-3)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this